{'fraction_non_alphanumeric': 0.033962264150943396, 'fraction_numerical': 0.01981132075471698, 'mean_word_length': 5.934640522875817, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
New thiourea and 1,3‐thiazolidin‐4‐one derivatives effective on the HIV‐1 virus

Thiourea derivatives have been reported to possess many biological activities, among them antiviral and antitumoral properties. As part of our continuing effort to develop new active compounds, we report the synthesis and the evaluation of new fifteen thiourea derivatives with 1,3‐benzothiazole‐2‐yl moiety, among them a group of biologically active (1–7) also underwent cyclization to 1,3‐thiazolidin‐4‐ones. Molecular structure of four compounds (4, 13, 15 and 3a) was determined by an X‐ray crystallography. We here report the evaluation of their cytotoxicity against human leukaemia/lymphoma‐ and solid tumour‐derived cell lines and of their antiviral activity against HIV‐1 and representatives of ssRNA and dsDNA viruses. Derivative 5 showed an interesting activity against HIV‐1 wild type and against variants carrying clinically relevant mutations. A colorimetric enzyme immunoassay clarified its mode of action as a non‐nucleoside inhibitor of the reverse transcriptase.